Publications by authors named "R M Kos"

Background: The highly effective Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulator, elexacaftor-tezacaftor-ivacaftor, is now widely being used by people with cystic fibrosis. However, few independent studies have detailed the pharmacokinetics (PK) of CFTR modulators. Blood collection by venipuncture is the gold standard for PK measurements, but it is invasive.

View Article and Find Full Text PDF

Background: Consistent use of reliable and clinically appropriate outcome measures is a priority for clinical trials, with clear definitions to allow comparability. We aimed to develop a core outcome set (COS) for pulmonary disease interventions in primary ciliary dyskinesia (PCD).

Methods: A multidisciplinary international PCD expert panel was set up.

View Article and Find Full Text PDF

: The coronavirus disease 2019 (COVID-19) pandemic has led to the death of almost 7 million people, however, with a cumulative incidence of 0.76 billion, most people survive COVID-19. Several studies indicate that the acute phase of COVID-19 may be followed by persistent symptoms including fatigue, dyspnea, headache, musculoskeletal symptoms, and pulmonary functional-and radiological abnormalities.

View Article and Find Full Text PDF

Volatile organic compounds (VOCs) found in exhaled breath continue to garner interest as an alternative diagnostic tool in pulmonary infections yet, their clinical integration remains a challenge with difficulties in translating identified biomarkers. Alterations in bacterial metabolism secondary to host nutritional availability may explain this but is often inadequately modelled . The influence of more clinically relevant nutrients on VOC production for two common respiratory pathogens was investigated.

View Article and Find Full Text PDF
Article Synopsis
  • Elexacaftor/tezacaftor/ivacaftor (ETI) is effective in treating cystic fibrosis patients with specific genetic mutations, showing positive results in a real-life study with Dutch patients.
  • The study tracked lung function (FEV), body mass index (BMI), and adverse events over 12 months, with significant improvements observed after starting ETI.
  • The treatment was well tolerated, resulting in increased lung function and BMI, fewer exacerbations, and only mild side effects such as rash and stomach aches.
View Article and Find Full Text PDF